Abstract
1736O - IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have